Miguel Mugica-Alvarez
Sama, AS, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
TXNIP upregulation controls metabolism and cell cycle during androgen deprivation therapy in prostate cancer.
Journal: Cell death & disease
Published: February 20, 2025
Tissue biomarkers in prostate cancer.
Journal: Archivos espanoles de urologia
Published: March 25, 2022
Interpretation of the metabolic study in renal lithiasis and its treatment
Journal: Semergen
Published: April 27, 2020
Renal cell carcinoma with (tubule) papillary architecture. Report of three cases and bibliographic review.
Journal: Archivos espanoles de urologia
Published: June 22, 2019
Usefulness of cold ureteral biopsy during radical cystectomy as a predictor of recurrence risk: Review of our series.
Journal: Archivos espanoles de urologia
Published: June 12, 2018
Results of adrenalectomy in lung cancer metastases.
Journal: Actas urologicas espanolas
Published: December 05, 2017
What primary care physicians should know about new markers in prostate cancer
Journal: Semergen
Published: June 22, 2017
Asymptomatic left ureter inguinal hernia during valsalva maneuver in a patient with complete left pyelo ureteral system duplication.
Journal: Archivos espanoles de urologia
Published: May 17, 2013
Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer.
Journal: The American journal of pathology
Published: April 25, 2012
Polyamine-modulated factor-1 methylation predicts Bacillus Calmette-Guérin response in patients with high-grade non-muscle-invasive bladder carcinoma.
Journal: European urology
Published: March 12, 2012
Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer.
Journal: The American journal of pathology
Published: November 14, 2011
Last Updated: 09/26/2026